Would you offer EGFR inhibitors to a patient with metastatic lung adenocarcinoma EGFR L858R mutation and concomitant NRAS mutation both on blood based testing?
Answer from: Medical Oncologist at Community Practice
This of course should be a rare event. Indeed, out of the hundreds of EGFR mutation positive patients I have seen, I have only encountered one case of concurrent KRAS G12C mutation and no concurrent NRAS mutation. The classic teaching is that KRAS mutations and EGFR mutations are mutually exclusive,...
Sign in or Register to read more